参考文献：
[1] Rakowska PD, Ryadnov MG.: Nano-enabled biomarker discovery and detection.Biomark Med. 2011 Jun;5(3):387-96.
[2] Baumgartner C., Osl, M., Netzer M., Baumgartner D.: Bioinformatic-driven search for metabolic biomarkers in disease.Journalof Clinical Bioinformatics.2011, 1:2.
[3] Sanchez-Carbayo M.: Antibody microarrays as tools for biomarker discovery.Methods Mol Biol 2011;785:159-82.
[4] Dunn D.A, Apanovitch D., Follettie M., He T., Ryan T.: Taking a Systems Approach to the Identification of Novel Therapeutic Targetsand Biomarkers.Current Pharmaceutical Biotechnology, 2010, 11, 721-734.
[5] Ray S., Mehta G., Srivastava S.: Label-free detection techniques for protein microarrays: Prospects, merits and challenges.Proteomics.2010, 10, 731–748.
[6] Ciordia S, de Los Ríos V, Albar JP.: Contributions of advanced proteomics technologies to cancer diagnosis.Clin Transl Oncol.2006 Aug;8(8):566-80.
[7] William CS Cho:Contribution of oncoproteomics to cancer biomarker discovery. Molecular Cancer 2007, 6:25.
[8] Celis JE, Gromov P: Proteomics in translational cancer research: toward an integrated approach. Cancer Cell 2003,3:9-15.
[9] Xing X, Lai M, Gartner W, Xu E, Huang Q, Li H, Chen G: Identification of differentially expressed proteins in colorectal cancer byproteomics: down-regulation of secretagogin. Proteomics 2006, 6:2916-2923.
[10] Nishimori T, Tomonaga T, Matsushita K, Kodera Y, Maeda T, Nomura F, Matsubara H, Shimada H, Ochiai T: Proteomic analysisof primary esophageal squamous cell carcinoma reveals downregulation of a cell adhesion protein,periplakin.Proteomics 2006, 6:1011-1018.
[11] Kang HJ, Koh KH, Yang E, Oh-Ishi M, You KT, Kim HJ, Paik YK, Kim H: Differentially expressed proteins in gastrointestinal stromal tumors with KIT and PDGFRA mutations. Proteomics 2006, 6:1151-1157.
[12] Lee IN, Chen CH, Sheu JC, Lee HS, Huang GT, Yu CY, Lu FJ, Chow LP: Identification of human hepatocellular carcinoma-related biomarkers by two-dimensional difference gel electrophoresis and mass spectrometry. J Proteome Res 2005, 4:2062-2069.
[13] Maciel CM, Junqueira M, Paschoal ME, Kawamura MT, Duarte RL, Carvalho Mda G, Domont GB: Differential proteomic serum pattern of low molecular weight proteins expressed by adenocarcinoma lung cancer patients. J Exp Ther Oncol 2005, 5:31-38.
[14] Doustjalali SR, Yusof R, Govindasamy GK, Bustam AZ, Pillay B, Hashim OH: Patients with nasopharyngeal carcinoma demonstra teenhanced serum and tissue ceruloplasmin expression. J Med Invest 2006, 53:20-28.
[15] Ahmed N, Oliva KT, Barker G, Hoffmann P, Reeve S, Smith IA, Quinn MA, Rice GE: Proteomic tracking of serum protein isoformsas screening biomarkers of ovarian cancer.Proteomics 2005, 5:4625-4636.
[16] Bloomston M, Zhou JX, Rosemurgy AS, Frankel W, Muro-Cacho CA, Yeatman TJ: Fibrinogen gamma overexpression in pancreatic cancer identified by large-scale proteomic analysis of serum samples.Cancer Res 2006, 66:2592-2599.
[17] Ornstein DK, Tyson DR: Proteomics for the identification of new prostate cancer biomarkers.Urol Oncol 2006, 24:231-236.
[18] Buhimschi C.S., Bhandari V., Dulay A.T., Nayeri U.A., AbdelRazeq S.S., Pettker C.M., Thung S., Zhao GM., Han Y.W., Bizzarro M.,Buhimschi I.A.: Proteomics Mapping of Cord Blood Identifies Haptoglobin ‘‘Switch-On’’ Pattern as Biomarker of Early-Onset Neonatal Sepsis in Preterm Newborns. PloS ONE. 2011, October, 6,10,e26111.
[19] Pawlik TM, Hawke DH, Liu Y, Krishnamurthy S, Fritsche H, Hunt KK, Kuerer HM: Proteomic analysis of nipple aspirate fluid from women with early-stage breast cancer using isotope-coded affinity tags and tandem mass spectrometry reveals differentialexpression of vitamin D binding protein. BMC Cancer 2006, 6:68.
[20] Madoz-Gurpide J, Lopez-Serra P, Martinez-Torrecuadrada JL, Sanchez L, Lombardia L, Casal JI: Proteomics-based validation of genomic data: applications in colorectal cancer diagnosis. Mol Cell Proteomics 2006, 5:1471-1483.
[21] Schwartz SA, Weil RJ, Thompson RC, Shyr Y, Moore JH, Toms SA, Johnson MD, Caprioli RM: Proteomic-based prognosis of brain tumor patients using direct-tissue matrix-assisted laser desorption ionization mass spectrometry. Cancer Res 2005, 65:7674-7681.
[22] Christopherson RI, Stoner K, Barber N, Belov L, Woolfson A, Scott M, Bendall L, Mulligan SP: Classification of AML using a monoclonal antibody microarray.Methods Mol Med 2006, 125:241-251.
[23] Fan G, Molstad M, Braziel RM, Standley M, Huang J, Rodgers W, Nagalla S: Proteomic profiling of mature CD10+ B-cell lymphomas.Am J Clin Pathol 2005, 124:920-929.
[24] Boja E, Rivers R, Kinsinger C, Mesri M, Hiltke T, Rahbar A, Rodriguez H: Restructuring proteomics through verification.Biomark Med.2010; 4(6): 799–803.
